

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Esketamine for treatment-resistant depression ID1414

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Janssen (esketamine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Association of Mental Health Providers • C.A.L.M • Charlie Waller Memorial Trust • Chinese Mental health Association • Chinese National Healthy Living Centre • Clifford Beers Foundation • Combat Stress • Depression UK • Making Space • Mental Health Foundation • Mental Health Matters • MIND • Muslim Council of Britain • PAPYRUS • Race Equality Foundation • Rethink • SANE • South Asian Health Foundation • Specialised Healthcare Alliance • The Matthew Trust • Together • United Response • WISH - A Voice for women's mental health <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Counselling and Psychotherapy • British Association for Psychopharmacology • British Association of Behavioural and 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Council for Wales • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Hafal • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • MIND Cymru • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Social Care Institute for Excellence • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (amitriptyline, citalopram, duloxetine, escitalopram, imipramine, lofepramine, mirtazapine, fluoxetine, paroxetine, quetiapine, sertraline and venlafaxine) • Amneal Pharma Europe (duloxetine, paroxetine) • Arristo Pharma (quetiapine) • AstraZeneca (quetiapine) • Aurobindo Pharma (citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, quetiapine,

Provisional matrix for the proposed technology appraisal of esketamine for treatment-resistant depression ID1414 Issue date: July 2018

Consultees	Commentators (no right to submit or appeal)
<p>Cognitive Psychotherapies</p> <ul style="list-style-type: none"> • British Association of Occupational Therapists and College of Occupational Therapists • British Geriatrics Society • British Neuropsychiatry Association • British Psychoanalytic Council • British Association of Social Workers • British Psychological Society • British Psychotherapy Foundation • College of Mental Health Pharmacy • Counsellors and Psychotherapists in Primary Care • Health and Care Professions Council • Mental Health Nurses Association • Primary Care Mental Health and Education • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Council for Psychotherapy <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Barking & Dagenham CCG • NHS England • NHS Walsall CCG • Welsh Government 	<ul style="list-style-type: none"> sertraline and venlafaxine) • Chiesi (venlafaxine) • Consilient Health (duloxetine, escitalopram, quetiapine and venlafaxine) • Creo Pharma (lofepramine and trazodone) • Dexcel Pharma (venlafaxine) • Dr Reddys Labs (duloxetine, fluoxetine and sertraline) • Fontus heath (quetiapine) • GlaxoSmithKline (paroxetine) • HBS Healthcare (duloxetine) • King Pharmaceuticals (nortriptyline) • Kyowa Kirin (phenelzine) • Lilly UK (duloxetine and fluoxetine) • Lundbeck (citalopram, escitalopram, vortioxetine) • Lupin (sertraline) • Marlborough (doxepin) • Merck Sharp & Dohme (mirtazapine) • Mylan (citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, paroxetine, quetiapine, trazodone and venlafaxine) • Par Laboratories Europe (fluoxetine) • Pfizer (reboxetine, sertraline and venlafaxine) • Rivopharm (citalopram, trazodone) • Sandoz (citalopram, paroxetine and quetiapine) • Servier (agomelatine) • Sun Pharmaceuticals (sertraline and venlafaxine) • Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine) • Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine and venlafaxine) • Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine)

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="818 309 1189 342"><u>Relevant research groups</u></p> <ul data-bbox="818 349 1422 875" style="list-style-type: none"> • Campbell Collaboration Social Welfare Group • Careif • Cochrane Depression Anxiety and Neurosis Group • Health Services Research Unit, Department of Public Health, University of Oxford • Institute of Psychiatry • Joseph Rowntree Foundation • MRC Clinical Trials Unit • National Institute for Health Research • National Primary Care Research & Development Centre <p data-bbox="818 913 1284 947"><u>Associated Public Health groups</u></p> <ul data-bbox="818 954 1173 1019" style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.